The University of Chicago Header Logo

Connection

Thomas F. Gajewski to Mice, Knockout

This is a "connection" page, showing publications Thomas F. Gajewski has written about Mice, Knockout.
Connection Strength

1.411
  1. Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy. J Immunother Cancer. 2024 Oct 26; 12(10).
    View in: PubMed
    Score: 0.172
  2. Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res. 2018 01; 6(1):14-24.
    View in: PubMed
    Score: 0.106
  3. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017 05 08; 31(5):711-723.e4.
    View in: PubMed
    Score: 0.102
  4. Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA. J Immunol. 2016 Apr 01; 196(7):3191-8.
    View in: PubMed
    Score: 0.094
  5. Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature. J Immunol. 2014 Oct 15; 193(8):4254-60.
    View in: PubMed
    Score: 0.085
  6. Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol. 2013 Oct; 55(3-4):283-91.
    View in: PubMed
    Score: 0.077
  7. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol. 2012 Mar 15; 188(6):2630-42.
    View in: PubMed
    Score: 0.071
  8. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011 Sep 26; 208(10):2005-16.
    View in: PubMed
    Score: 0.069
  9. Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-?1 phosphorylation. J Immunol. 2011 Jan 15; 186(2):784-90.
    View in: PubMed
    Score: 0.066
  10. Beta-catenin does not regulate memory T cell phenotype. Nat Med. 2010 May; 16(5):513-4; author reply 514-5.
    View in: PubMed
    Score: 0.063
  11. Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway. J Immunol. 2009 May 15; 182(10):6022-30.
    View in: PubMed
    Score: 0.059
  12. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol. 2005 Apr 15; 174(8):4670-7.
    View in: PubMed
    Score: 0.044
  13. ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. J Immunol. 2005 Mar 15; 174(6):3416-20.
    View in: PubMed
    Score: 0.044
  14. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol. 2003 Nov 01; 171(9):4574-81.
    View in: PubMed
    Score: 0.040
  15. CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol. 2001 Sep 15; 167(6):3123-8.
    View in: PubMed
    Score: 0.035
  16. Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol. 2001 Mar 15; 166(6):3900-7.
    View in: PubMed
    Score: 0.033
  17. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol. 2000 Dec 01; 165(11):6024-8.
    View in: PubMed
    Score: 0.033
  18. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol. 1999 Oct 15; 163(8):4109-13.
    View in: PubMed
    Score: 0.030
  19. The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit Rev Oncog. 1999; 10(3):247-60.
    View in: PubMed
    Score: 0.029
  20. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol. 1998 Oct 01; 161(7):3347-56.
    View in: PubMed
    Score: 0.028
  21. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015 Jun 25; 6:7458.
    View in: PubMed
    Score: 0.022
  22. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014 Nov 20; 41(5):843-52.
    View in: PubMed
    Score: 0.021
  23. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014 Nov 20; 41(5):830-42.
    View in: PubMed
    Score: 0.021
  24. CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells. J Immunol. 2009 Jun 01; 182(11):6736-43.
    View in: PubMed
    Score: 0.015
  25. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009 Aug 20; 114(8):1545-52.
    View in: PubMed
    Score: 0.015
  26. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
    View in: PubMed
    Score: 0.013
  27. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol. 2002 Jul 15; 169(2):633-7.
    View in: PubMed
    Score: 0.009
  28. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 2001 Sep 01; 167(5):2555-60.
    View in: PubMed
    Score: 0.009
  29. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. J Immunol. 1997 Nov 15; 159(10):4665-75.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.